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Bradykinin, But Not Muscarinic, Inhibition of M-Current in Rat
Sympathetic Ganglion Neurons Involves Phospholipase C-b4
Jane E. Haley, Fe C. Abogadie, Jose M. Fernandez-Fernandez, Mariza Dayrell, Yvonne Vallis,
Noel J. Buckley, and David A. Brown
Wellcome Laboratory for Molecular Pharmacology, Department of Pharmacology, University College London, London,
WC1E 6BT, United Kingdom
Rat superior cervical ganglion (SCG) neurons express low-
threshold noninactivating M-type potassium channels (IK(M) ),
which can be inhibited by activation of M1 muscarinic receptors
(M1 mAChR) and bradykinin (BK) B2 receptors. Inhibition by
the M1 mAChR agonist oxotremorine methiodide (Oxo-M) is
mediated, at least in part, by the pertussis toxin-insensitive
G-protein Gaq (Caulfield et al., 1994; Haley et al., 1998a),
whereas BK inhibition involves Gaq and/or Ga11 (Jones et al.,
1995). Gaq and Ga11 can stimulate phospholipase C-b (PLC-
b), raising the possibility that PLC is involved in IK(M) inhibition
by Oxo-M and BK. RT-PCR and antibody staining confirmed
the presence of PLC-b1, -b2, -b3, and -b4 in rat SCG. We have
tested the role of two PLC isoforms (PLC-b1 and PLC-b4) using
antisense-expression constructs. Antisense constructs, con-
sisting of the cytomegalovirus promoter driving antisense cRNA
corresponding to the 39-untranslated regions of PLC-b1 and
PLC-b4, were injected into the nucleus of dissociated SCG
neurons. Injected cells showed reduced antibody staining for
the relevant PLC-b isoform when compared to uninjected cells
48 hr later. BK inhibition of IK(M) was significantly reduced 48 hr
after injection of the PLC-b4, but not the PLC-b1, antisense-
encoding plasmid. Neither PLC-b antisense altered M1 mAChR
inhibition by Oxo-M. These data support the conclusion of
Cruzblanca et al. (1998) that BK, but not M1 mAChR, inhibition
of IK(M) involves PLC and extends this finding by indicating that
PLC-b4 is involved.
Key words: M-current; muscarinic receptor; bradykinin;
phospholipase C-b; antisense; superior cervical ganglion
neuron
The M-type potassium current (IK(M)) is a noninactivating po-
tassium current present in various peripheral and central neurons,
including rat superior cervical ganglion (SCG) neurons (for re-
view, see Brown, 1988). It is activated in the subthreshold range
for action potentials and increases with membrane depolarization
and may, therefore, be involved in controlling cell excitability,
because inhibition of this current results in depolarization and
increased action potential discharge. IK(M) in SCG can be inhib-
ited by stimulating various receptors including the M1 muscarinic
receptor (M1 mAChR; Marrion et al., 1989; Bernheim et al.,
1992; Hamilton et al., 1997) and bradykinin (BK) B2 receptor
(Jones et al., 1995), both of which couple via Bordetella pertussis
toxin (PTX)-insensitive GTP-binding proteins (G-proteins). We
have previously demonstrated that the a subunit of Gq mediates
inhibition by M1 mAChR agonists (Haley et al., 1998a) and that
Gaq and/or Ga11 is required for inhibition by BK (Jones et al.,
1995). Because both Gaq and Ga11 are known to stimulate
PLC-b (Singer et al., 1997), we have now used antisense directed
at two PLC-b isoforms (PLC-b1 and PLC-b4) to deplete the cells
of these enzymes and so determine whether either is required for
inhibition of IK(M) by M1 mAChR agonists or BK.
Some of this data has been previously presented in abstract
form (Haley et al., 1998b)
MATERIALS AND METHODS
DNA plasmids. The constructs used in this study were made by PCR
cloning using standard molecular techniques (Abogadie et al., 1997).
Primers that were deemed specific for each target PLC-b isoform were
used in PCR, and the products were TA-cloned into pCR3 or pCR3.1
(Invitrogen, San Diego, CA). Antisense orientation was confirmed by
sequencing. The clones are as follows, in 59 to 39 orientation [nucleotide
(nt); plus and minus signs indicating downstream and upstream, respec-
tively, of the stop codon]: PLC-b1 antisense (clone 239–8), nt 122 to
1172; PLC-b2 antisense (clone F128–5), nt 2536 to 2309; PLC-b3
antisense (clone E92–18), nt 293 to 167; PLC-b4 antisense (C58–13), nt
15 to 1386.
Cell culture. Sympathetic neurons were isolated from SCG of 15- to
19-d-old Sprague Dawley rats and cultured using standard procedures as
described previously (Delmas et al., 1998).
Microinjection. DNA plasmids, purified using maxiprep columns (Qia-
gen, Hilden, Germany), were diluted to 400 mg/ml in calcium- and
glucose-free Krebs’ solution (290 mOsm/l; pH 7.3) containing 0.5%
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FITC-dextran (70,000 MW) and pressure injected into the nucleus of
SCG neurons 2 d in culture using an Eppendorf microinjector (Hamburg,
Germany). Cells were maintained in culture for a further 2 d, and a
survival rate of 75–85% was obtained.
Electrophysiology. IK(M) was measured from SCG neurons cultured for
5 d, using the amphotericin-B perforated-patch technique (Horn and
Marty, 1988; Rae et al., 1991). Patch electrodes (1.5–4 MV) were filled by
dipping the tip for 40 sec into filtered internal solution that comprised (in
mM): potassium acetate 80, KCl 30, HEPES 40, MgCl2 3 (adjusted to pH
7.3–7.4 with KOH, and 280 mOsmol/ l with K acetate). The pipette was
then back-filled with internal solution containing 0.07–0.1 mg/ml
amphotericin-B. High resistance seals (.2 GV) were initially achieved,
and after amphotericin-B permeabilization, access resistances were gen-
erally ,25 MV. SCG neurons were perfused at 5–10 ml/min at 32°C with
an external solution consisting of (in mM): NaCl 120, KCl 3, HEPES 5,
NaHCO3 23, glucose 11, MgCl2 1.2, CaCl2 2.5, and tetrodotoxin (TTX)
0.0005, pH 7.4. Cells were voltage-clamped at approximately 225 mV to
preactivate IK(M) using a switching amplifier (Axoclamp-2A; Axon In-
struments, Foster City, CA; switching frequencies 3–5 kHz, filter 0.1
kHz). IK(M) was measured from the slow deactivation relaxation after a 1
sec jump to a command potential of approximately 255 mV (Haley et al.,
1998a), and inhibition was measured as the fractional reduction in the
amplitude of this deactivation relaxation in response to either cumula-
tively increasing concentrations of oxotremorine methiodide (Oxo-M;
Research Biochemicals, Natick, MA) or a single application of 1 nM BK
(Bachem, Torrance, CA) (see Fig. 2). Data were collected and analyzed
using pClamp6 software (Axon Instruments) and expressed as mean 6
SEM. Statistical analysis of the Oxo-M dose–response curves used two-
way ANOVA comparing all treatments across all concentrations of
agonist. If a significant effect of treatment was found overall, further
analysis was performed using two-way ANOVA to determine which
treatment groups contributed to this significance. The bradykinin data
were analyzed using Student’s t test with Welch’s correction. p values ,
0.05 were considered significant.
Reverse transcription PCR. RNA was extracted from rat SCGs using
RNAzol B (Biogenesis Ltd.) and reverse-transcribed using oligo-dT and
mouse murine leukemia virus reverse transcriptase (Promega, Madison,
WI). The oligonucleotide primers used in the PCR were those that were
deemed least conserved among the different PLCb isoforms to ensure
specificity in the amplification. The primers are as follows (“u” denotes
sequence in the 39 untranslated region, “s” denotes sense primer, and “a”
denotes antisense primer): PLCb-1 u22 s/u199a; PLCb-2 3111 s/3319a;
PLCb-3 3564 s/u45a; PLCb-4 u5 s/u366a. Cycling conditions were 95°C
for 5 min and then 35 cycles of 95°C for 30 sec, 58°C for 30 sec, and 72°C
for 1 min followed by a final extension step of 72°C for 10 min.
Immunocytochemistry. SCG neurons, cultured and injected as de-
scribed above, were fixed in acetone and stained using specific polyclonal
antibodies against PLC-b1 (sc-205), PLC-b2 (sc-206), PLC-b3 (sc-403),
and PLC-b4 (sc-404) (Santa Cruz Biotechnology, Santa Cruz, CA) di-
luted either 1:1000 or 1:500. Specificity of the antibodies was confirmed
by pre-absorbing the antibody with 6- to 10-fold excess (by weight) of the
relevant immunogenic peptides (also from Santa Cruz Biotechnology).
All dishes of SCG neurons recorded in the electrophysiology experi-
ments were subsequently fixed and stained. The alkaline phosphatase
substrate system used was 5-bromo-4-chloro-3-indoxyl phosphate and
nitroblue tetrazolium chloride (BCIP/NBT) (Dako, Carpinteria, CA).
Because the purple–blue product was too dark to quantitate photomet-
rically, we have assessed whether there was an overall qualitative reduc-
tion in staining by comparing each injected cell with its nearest unin-
jected neighbor and determining (by eye) whether the level of staining
was equal to or less than that of the uninjected cell. Using this method we
have estimated the proportion of cells with a visible reduction in staining
(regardless of the magnitude of this reduction) 48 hr after injection of the
antisense plasmid.
RESULTS
PLC-b isoforms expressed in SCG
RT-PCR demonstrated the presence of mRNA for all four iso-
forms of PLC-b (1, 2, 3, and 4) in rat SCG (Fig. 1A) while the
protein for all isoforms was detected immunocytochemically in
cultured SCG neurons. Intranuclear injection of antisense against
PLC-b1 and PLC-b4 resulted in a reduction in the level of
staining for the relevant enzyme 48 hr later (Fig. 1B,C). The
PLC-b1 antisense was highly effective and clearly reduced
PLC-b1 staining in 37 of 53 neurons (70%; n 5 7 dishes of cells)
without altering levels of PLC-b2 (1 of 12 cells showed reduced
staining; 8%; n 5 3 dishes), PLC-b3 (1 of 12 cells; 8%; n 5 3
dishes), or PLC-b4 (0 of 13 cells; n 5 2 dishes). The PLC-b4
antisense was less effective but still reduced visible PLC-b4
staining in 12 of 32 cells (38%; n 5 10 dishes of cells). Although
the PLC-b4 antisense was designed to specifically target the
PLC-b4 isoform, it also reduced levels of PLC-b1 (11 of 21 cells;
52%; n 5 6 dishes) but did not alter PLC-b3 staining (1 of 9 cells;
11%; n 5 3 dishes) or PLC-b2 staining (1 of 21 cells; 5%; n 5 2
dishes). Antisense-encoding plasmids were also designed against
the remaining PLC-b isoforms, but neither the PLC-b2 antisense
(2 of 39 cells; 5%; n 5 5 dishes) nor the PLC-b3 antisense (1 of
9 cells; 11%; n 5 5 dishes) reduced staining of its respective
protein. Electrophysiological data with these ineffective antisense
clones is not shown although, as expected, they did not alter IK(M)
modulation by Oxo-M or BK, confirming that injection of DNA
plasmids per se does not alter modulation of IK(M).
Effect of PLC-b antisense plasmids on IK(M) inhibition
by a muscarinic agonist and by bradykinin
Intranuclear injection of antisense against PLC-b1 or PLC-b4 did
not alter the amplitude of IK(M). Mean values (in picoamperes per
Figure 1. A, RT-PCR indicating the presence of mRNA for PLC-b1,
PLC-b2, PLC-b3, and PLC-b4 in rat SCG neurons. Lanes labeled M are
size markers; lane B is a blank where no template was included in the
PCR reaction. B, SCG neuron injected with antisense against PLC-b1
(along with a fluorescent marker; lef t panel ) and stained for PLC-b1 (right
panel ). C, SCG neuron injected with PLC-b4 antisense and stained for
PLC-b4.
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picofarad) 6 SEM were: uninjected cells, 2.91 6 0.41 (n 5 8);
PLC-b1 antisense, 2.39 6 0.52 (n 5 10); and PLC-b4 antisense,
2.33 6 0.36 (n 5 10). The resting membrane potential was not
altered in cells with reduced PLC-b1 or -b4 levels (uninjected:
258.1 6 2.0 mV, n 5 10; PLC-b1 antisense: 260.3 6 1.9 mV, n 5
13; PLC-b4 antisense: 258.8 6 1.5 mV, n 5 11).
Neither antisense affected M1 mAChR-mediated inhibition of
IK(M) tested 48 hr later (when a reduction in the levels of these
enzymes was observed). The dose–response curves to the mus-
carinic agonist Oxo-M in PLC-b1 or PLC-b4-depleted cells were
not significantly different from one another or from that in unin-
jected neurons: IC50 values and Hill slopes were 0.4 mM and 1.1
for uninjected neurons, 0.8 mM and 1.0 for PLC-b1 antisense-
injected neurons, and 0.5 mM and 1.1 for PLC-b4 antisense-
injected cells (Figs. 2, 3). In contrast, inhibition by BK was
reduced in cells injected with the PLC-b4, but not PLC-b1
antisense-expressing plasmid: 1 nM BK produced 28.5 6 6.8%
inhibition in uninjected cells (n 5 8), 30.8 6 7.9% in PLC-b1
antisense-injected neurons (n 5 10), but only 12.5 6 2.0% inhi-
bition in PLC-b4 antisense-injected cells (n 5 10; p , 0.05
compared with uninjected or PLC-b1 antisense-injected neurons)
(Fig. 4).
DISCUSSION
The principal inference to be drawn from these experiments is
that activation of PLC-b4 probably contributes to the inhibition
of IK(M) produced by stimulating BK receptors, but not to that
produced by activating M1 muscarinic acetylcholine receptors.
This differentiation accords with, and amplifies, previous conclu-
sions of Cruzblanca et al. (1998) regarding the differential partic-
ipation of the PLC pathway in M-current inhibition after stimu-
lation of these two G protein-coupled receptors.
RT-PCR clearly demonstrated the presence of mRNA for
PLC-b1, -b2, -b3, and b4 in rat SCG. Staining of cultured SCG
neurons using specific antibodies also confirmed the presence of
these proteins. Using antisense-encoding DNA plasmids we were
able to reduce the levels of PLC-b1 and PLC-b4 in SCG neurons.
Although both PLC-b1 and PLC-b4 have been shown to exist as
two splice variants (Bahk et al., 1994; Kim et al., 1998), the
antisense sequences we have used should target both variants of
each enzyme. Indeed, the PLC-b1 antisense reduced PLC-b1
staining in both the cytosol and the nucleus of cultured SCG
neurons (Fig. 1B), suggesting that levels of both splice variants
were reduced because, in C6Bu-1 cells, PLC-b1a has been shown
to be present mainly in the cytosol, whereas PLC-b1b was present
in the nucleus (Bahk et al., 1998). As we found previously with
antisense against Gaq and Ga11 (Haley et al., 1998a), not all the
antisense sequences designed were effective, and the constructs
driving expression of antisense PLC-b2 and antisense PLC-b3
were unable to reduce staining of their target proteins.
Although the PLC-b1 antisense resulted in a robust reduction
of PLC-b1 levels (Fig. 1B), there was no reduction in either
Oxo-M or BK inhibition of IK(M). By contrast, the PLC-b4 anti-
sense reduced BK inhibition of IK(M) but left Oxo-M inhibition
Figure 2. Time course of normalized IK(M) amplitude during cumula-
tively increasing concentrations of Oxo-M and a single application of
bradykinin, as indicated, for neurons injected with PLC-b1 and PLC-b4
antisense plasmids. IK(M) was recorded every 5 sec (30 sec during wash-
out). Each Oxo-M concentration was applied for 1 min, and bradykinin
was applied for 1.5 min. Oxo-M and bradykinin were applied to the same
neurons, and wash-out of Oxo-M continued during the break in the x-axis.
IK(M) amplitudes were renormalized before bradykinin application to
eliminate any differences in recovery from the Oxo-M application.
Figure 3. PLC-b1 and PLC-b4 antisense do not alter inhibition of IK(M)
by Oxo-M. Left panel, Dose–response curves (mean 6 SEM, plus best fit
curve) for Oxo-M inhibition of IK(M) in antisense plasmid-injected SCG
neurons. There is no significant difference between neurons injected with
PLC-b1 antisense (n 5 11), PLC-b4 antisense (n 5 10), and the unin-
jected neurons (n 5 10). Right panel, Typical IK(M) deactivation relax-
ations elicited by a 230 mV step for 1 sec from a holding potential of 225
mV, in the absence and presence of 1 and 10 mM Oxo-M for cells injected
with either PLC-b1 or PLC-b4 antisense plasmids (as indicated). The
dotted lines represent 0 pA, and the calibration bars indicate 250 pA.
Haley et al. • Bradykinin Inhibition of IK(M) Involves PLC-b4 J. Neurosci., 2000, Vol. 20 3 of 5
unaltered. This difference between BK and Oxo-M is unlikely to
be caused by the fact that Oxo-M is a more “efficacious” inhibitor
of IK(M) (in the sense that it produced a larger maximum inhibi-
tion), because the response to even a low concentration (0.3 mM)
of Oxo-M that matched that produced by BK was unaffected by
the PLC-b4 antisense (Fig. 3). Also, the concomitant reduction in
PLC-b1 staining produced by the PLC-b4 antisense is unlikely to
be responsible for the loss of BK inhibition because the PLC-b1
antisense produced a greater and more consistent reduction in
PLC-b1 protein levels yet did not alter this response. At the very
least, therefore, it is reasonable to conclude that BK inhibition of
IK(M) requires PLC-b4 activation to a demonstrably greater ex-
tent than Oxo-M inhibition. In this respect, our results are in
harmony with the conclusions of Cruzblanca et al. (1998) that
inhibition of IK(M) by BK, but not by Oxo-M, involves PLC
activation.
In the absence of positive controls, we cannot make any firm
conclusion from the negative effect of PLC-b1 antisense—for
example, it is possible that sufficient PLC-b1 protein remained
after antisense depletion to continue to drive IK(M) inhibition.
Likewise, because antisense constructs against PLC-b2 or
PLC-b3 did not reduce the levels of the cognate proteins, we
cannot make any conclusions regarding the roles of these two
isoforms in IK(M) inhibition. Nevertheless, a potential selective
involvement of PLC-b4 in the action of BK would provide an
interesting correlation with the results of our previous experi-
ments using overexpressed bg and constitutively active a-subunits
(Haley et al., 1998a), showing that it is the a subunit of Gq or G11,
not the bg subunit, that mediates inhibition of IK(M), because, of
the four isoforms of PLC, it is only PLC-b4 that is solely activated
by the a-subunit and not by bg-subunits (Singer et al., 1997).
At first sight, our data (and also those of Cruzblanca et al.,
1998) would seem to be in conflict with those of Hildebrandt et al.
(1997), who found that an inhibitor of PLC did not alter BK
inhibition of the IK(M)-like current in NG108 cells. Recent ad-
vances in our understanding of the channels underlying the IK(M),
however, provide a possible explanation for this discrepancy. It is
now thought that the IK(M)-like current in NG108 cells actually
comprises two separate currents: the first has similarities with
IK(M) in SCG and probably results from KCNQ2/3 channel activ-
ity (cf. Wang et al., 1998), whereas the second, slower current, is
pharmacologically distinct and probably results from merg chan-
nel activity (Selyanko et al., 1999). The “SCG-like” (KCNQ)
IK(M) in NG108 cells is sensitive to blockade by TEA (Selyanko et
al., 1999): because the experiments presented in Hildebrandt et
al. (1997) were all performed in the presence of TEA, they were
probably examining BK inhibition of the merg based IK(M)-like
current, which may be inhibited by a different mechanism from
IK(M) in SCG.
IK(M) channels in SCG neurons can be inhibited by high con-
centrations of intracellular Ca21 (Selyanko and Brown, 1996).
Because BK can increase intracellular Ca21 levels in rat SCG
neurons (Cruzblanca et al., 1998; del Rio et al., 1999), it is
possible that BK may inhibit IK(M) by stimulating PLC-b4 to
generate IP3 and thereby mobilizing Ca
21 from internal stores
(Cruzblanca et al., 1998). We attempted to determine whether BK
induced Ca21 rises in SCG require PLC-b4 activation but found
that the Ca21 rises we detected were small and very variable,
making assessment of any antisense effect impossible (our unpub-
lished data). M1 mAChR mediated inhibition of IK(M) is unlikely
to involve Ca21 as a messenger because agonists at this receptor
do not appear to raise internal Ca21 levels in SCG (Cruzblanca
et al., 1998). Even when modest rises in internal Ca21 levels have
been observed (e.g., under conditions where the cells are de-
polarized) these rises are not correlated with inhibition of IK(M)
(del Rio et al., 1999). Furthermore, buffering of intracellular
Ca21 by the Ca21 chelator BAPTA attenuates BK inhibition of
IK(M), but leaves Oxo-M inhibition intact (Cruzblanca et al.,
1998).
Thus, both the experiments of Cruzblanca et al. (1998) and
those described in the present paper lead to the conclusion that
the inhibition of M-current in rat SCG neurons produced by
stimulating muscarinic or bradykinin receptors proceeds via dif-
ferent intracellular pathways. Because both receptors can couple
to the same family of G-proteins and because both are intrinsi-
cally capable of inducing inositol phosphate production within
these neurons (del Rio et al., 1999), the reason for this divergence
in M channel signaling is not yet clear. Nevertheless, it highlights
Figure 4. Inhibition of IK(M) by bradykinin is attenuated in neurons
injected with PLC-b4 antisense. Left panel, Mean data 6 SEM for
inhibition of IK(M) by 1 nM BK. Neurons injected with PLC-b4 antisense
produced significantly less inhibition compared to either uninjected or
PLC-b1 antisense plasmid-injected neurons (*p , 0.05). Right panel,
Typical IK(M) waveforms after a 1 sec step in the presence and absence of
1 nM bradykinin with either PLC-b1 or PLC-b4 antisense plasmid-
injected neurons (as indicated). The dotted lines represent 0 pA, and the
calibration bars represent 250 pA.
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the point that M channels may be regulated by more than one
mechanism.
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